Acute Pancreatitis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Acute Pancreatitis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The acute pancreatitis market studied is expected to grow with an estimated CAGR of 5.07%, over the forecast period (2022-2027).

There has been a significant change in the market due to the outbreak of the COVID-19 pandemic. Most gastrointestinal procedures have been suspended which led to a decrease in device-based treatments such as intravenous fluid and ERCP. The Centers for Disease Control and Prevention (CDC), 2020 added multiple symptoms as a part of the COVID-19 presentation, which also includes gastrointestinal (GI) manifestations such as pancreatitis and other symptoms. However, factors such as lack of testing kits, reduced workforce, and lockdowns have prioritized the high-risk procedures and postponed or even cancel endoscopies in medium- to low-risk cases. Thereby, affecting the overall acute pancreatitis market.

Gallstones and heavy alcohol intake are key factors in causing acute pancreatitis, especially in the younger population. Alcohol consumption is linked to an increased risk of acquiring serious noncommunicable diseases such as liver cirrhosis, several malignancies, and cardiovascular diseases as well as mental and behavioral disorders, including alcohol dependency. According to a World Health Organization article titled "Alcohol" that was published in May 2022, the amount of alcohol consumed overall as well as the pattern of drinking, particularly patterns that are connected to episodes of heavy drinking, have a significant impact on both chronic and acute health outcomes. The Australian Bureau of Statistics reported that one in four Australians aged 18 and older surpassed the Australian Adult Alcohol Guideline in 2020–21 (25.8%) in a March 2022 article headlined "Alcohol use." Thus, the increasing prevalence of alcohol consumption is expected to increase the market growth by increasing the prevalence of acute pancreatitis.

Key Market TrendsIntravenous Fluids are Expected to Cover a Large Share in the Treatment Segment.

Acute Pancreatitis is related to heavy fluid loss and dehydration which can be fatal and may lead to the death of the patient. Intravenous administration of fluids in the body keeps the body hydrated and ensures proper blood flow to the rest of the organs of the body. Obesity is one of the key factors in market growth. The prevalence of chronic comorbidities is rising globally, and this has been accompanied by a growing interest in how these comorbidities affect patients with acute pancreatitis, according to a research study published in November 2021 and titled "Prevalence of Chronic Metabolic Comorbidities in Acute Pancreatitis and Its Impact on Early Gastrointestinal Symptoms during Hospitalization: A Prospective Cohort Study." In the early stages of acute pancreatitis, gastrointestinal symptoms are linked to pre-existing diabetes mellitus, obesity, metabolic syndrome, and metabolic syndrome. Thus, it is anticipated that the market will grow as obesity rates rise. The primary purpose of fluid resuscitation, according to another research study published in June 2022 under the title "Fluid Resuscitation," is to maintain organ perfusion (hemodynamics) and substrate delivery (oxygen, electrolytes, among other things) through the administration of fluid and electrolytes. When oral intake is not feasible, doctors can replace fluid losses by giving intravenous (IV) injections instead of using the enteral route. Thus, such advantages are expected to increase the adoption of intravenous fluid resuscitation and thus increase the market growth.

Thus, the abovementioned factors are expected to increase market growth.

North America Dominates the Market and Expected to do same in the Forecast Period

North America is expected to increase its market share in the future, owing to the well-established healthcare industry and rising incidence of Acute Pancreatitis (AP) in the region. The increasing population of people suffering from acute pancreatitis in the United States has caused an increase in this market. According to a research paper titled "Acute Pancreatitis" that was released in June 2022, acute pancreatitis is the primary reason for gastrointestinal-related hospitalization in the United States, and its prevalence is increasing. The population incidence has most recently been reported in the United States to be 600 to 700 per 100,000 persons, with 200,000 to 250,000 discharges per year due to acute pancreatitis. Thus, the increasing prevalence of acute pancreatitis is expected to increase market growth. Various clinical trials have been initiated in the region. For instance, the University of Liverpool began a clinical trial with the working title "Markers in Acute Pancreatitis-1 (MAP-1)" in March 2022. The MAP-1 study aims to validate pancreatic digesting enzyme and/or microRNA biomarkers for the detection and severity evaluation of drug-associated AP, for application to the evaluation of adverse responses to medications now under development or drugs already produced for other indications. The study will also evaluate the clinical relevance of these biomarkers in AP from other causes, although it is not intended to ascertain whether the biomarkers may replace amylase and/or lipase in the typical clinical diagnosis of AP or to differentiate between the numerous alternative diagnoses of AP. Thus, such clinical trials are expected to increase market growth.

Based on the aforementioned factors, the United States acute pancreatitis market is expected to increase in the forecast period.

Competitive Landscape

The acute pancreatitis market is fragmented and moderately competitive with several players across the globe. Due to limited treatment options available, there is high competition in the market. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases, many regional players are expected to be part of the acute pancreatitis market over the forecast period. Some of the major players in the market are Abbott Laboratories, Pfizer Inc., Merck & Co., Inc, GlaxoSmithKline, Baxter International Inc., Fresenius Kabi USA, Dynavax Technologies Corporation, B. Braun Melsungen AG, and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.